ClinicalTrials.gg
Active, not recruitingNCT02159495Updated Aug 26, 2026

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

A Phase 1 interventional study of cyclophosphamide and Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes in Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia and Early Relapse of Acute Myeloid Leukemia, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 195 studies in Leukemia, Biphenotypic, Acute with a site in United States — 38 open to participants now, 63 under way, 5 of them phase 3. Leukemia, Biphenotypic, Acute · United States.

Enrollment
93rd of 155
31 · median 42
Started
2015
with 6 others
Phase 1
63 of 195
8 open now
Primary completion
2027-07
later than 29 of 62 live
Registered
112th of 195
by date
Lead sponsor
4 of 195
City of Hope Medical Center

Among the 195 studies in Leukemia, Biphenotypic, Acute with a site in United States, this one is the 93rd largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2015, is one of 63 in phase 1, reaches primary completion later than 29 of the 62 other live ones, and was the 112th registered.

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

Browse Leukemia, Biphenotypic, Acute studies →

Open to participants now

38 of the 195 studies in Leukemia, Biphenotypic, Acute with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Leukemia, Biphenotypic, Acute with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded to previous treatment. An immune cell is a type of blood cell that can recognize and kill abnormal cells in the body. The immune cell product will be made from patient or patient's donor (related or unrelated) blood cells. The immune cells are changed by inserting additional pieces of deoxyribonucleic acid (DNA) (genetic material) into the cell to make it recognize and kill cancer cells. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Read the detailed description

PRIMARY OBJECTIVES: I. To examine the anti-tumor activity and safety of administering ex vivo expanded T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a co-stimulatory CD123-specific chimeric antigen receptor (CAR) as well as a truncated EGFR (CD123CAR-CD28-CD3zeta-EGFRt+ T cells [CD123+ CAR T cells]) following lymphodepletion for patients with CD123+ relapsed or refractory acute myeloid leukemia (AML) (arm 1), or CD123+ persistent or recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (arm 2). II. To determine the recommended Phase II dose (RP2D) for both arms (AML and BPDCN). SECONDARY OBJECTIVES: I. To assess activity in the form of CD123+ CAR T cell persistence, 6 month progression free survival (PFS 6mo) rate, and 1 year overall survival (OS) rate, and describe the immunogenicity of CD123R(EQ)28zeta/EGFRt+ T cells. TERTIARY OBJECTIVES: I. To assess impact on hematopoiesis, change from baseline in numbers of CD123+ blood cells, CD123 expression on malignant cells and hematopoietic cells, and the clinical efficacy of EGFRt mediated CAR T cell ablation.

OUTLINE: This is a dose-escalation study of autologous or allogeneic (related or unrelated donor) CD123+ CAR T cells. Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide intravenously (IV) on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR T cells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a dose-limiting toxicity (DLT) may receive a second infusion of CD123+ CAR T cells after 28 days. After completion of study treatment, patients are followed up at 24 hours, then every 2 days for up to 14 days, every week for 1 month, every month for 1 year and then yearly for 15 years.

03

Conditions studied

  • Adult Acute Myeloid Leukemia in Remission
  • Acute Biphenotypic Leukemia
  • Early Relapse of Acute Myeloid Leukemia
  • Late Relapse of Acute Myeloid Leukemia
  • Recurrent Adult Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Acute Myeloid Leukemia
  • Adult Acute Lymphoblastic Leukemia
  • Interleukin-3 Receptor Subunit Alpha Positive
  • Minimal Residual Disease
  • Refractory Acute Myeloid Leukemia
  • Untreated Adult Acute Myeloid Leukemia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ARM 1 - AML: Research patients enrolled are those patients with CD123+ AML de novo, or secondary OR participants who are at high risk for disease recurrence NOTE: CD123+ biphenotypic acute leukemia or CD123+ acute lymphoblastic leukemia (ALL) may also be considered but only after discussion with the study principal investigator (PI)

    • Relapsed AML is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts)
    • Refractory AML is defined as patients that have not achieved a first CR after 2 cycles of induction chemotherapy; for patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy
  • ARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 for BPDCN and who have persistent or recurrent disease in at least one of the following are eligible: peripheral blood, bone marrow, lymph nodes, spleen, cutaneous lesions or other sites OR participant who are at high risk for disease recurrence
  • FOR BOTH STUDY ARMS: Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry; cytogenetics, flow cytometry, and molecular studies (such as FMS-like tyrosine kinase-3 [FLT-3] status) will be obtained as per standard practice; however, for research participants who are at a high risk of recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN; CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry prior to start of lymphodepletion
  • performance status score >= 70
  • A >= 16 weeks at time of enrollment
  • Pediatric research participants must weigh > 50 kg
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • Calculated (absolute value) of >= 50 mL/minute or creatinine \< 2.0 mg/dl or \< 2 times for the research participant's age group
  • Serum =\< 3.0 mg/dL
  • (ALT) and aspartate aminotransferase (AST) =\< 5 times the institutional upper limits of normal
  • measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%
  • ONLY research participants experiencing hypoxia with oxygen saturation less than 92% are required to have diffusion capacity of carbon monoxide (DLCO) or (FEV1) > 45% predicted
  • Research participants' last dose of prior chemotherapy or radiation must be >= 2 weeks before leukapheresis

    * Note: the above criterion is not applicable if the research participant's donor is undergoing leukapheresis

  • If a research participant has undergone prior stem cell transplant, he/she must be off all for (GVHD) for at least 2 weeks before undergoing leukapheresis

    * Note: the above criterion is not applicable if the research participant's donor is undergoing leukapheresis

  • Negative serum or urine pregnancy test
  • All research participants must have the ability to understand and willingness to sign a written or age appropriate assent for pediatric patients

    * Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed; however, the research participant is allowed to proceed with lymphodepletion and T cell infusion only after the translated full consent form is signed

  • ELIGIBILITY TO PROCEED WITH PERIPHERAL BLOOD MONONUCLEAR CELL (PMBC) COLLECTION:

    * If research participant is undergoing leukapheresis:

    • He/she has acceptable venous access as assessed by Donor Apheresis Center or if venous access was not acceptable, a Hickman Catheter or temporary line was placed prior to scheduled leukapheresis
    • He/she has undergone prior alloSCT, they must be at least 2 weeks from having received the last dose of immunosuppressant medications to undergo PBMC collection for T cell manufacturing
    • His/her last dose of prior chemotherapy, immunotherapy or radiation is at least 2 weeks out from PBMC collection
  • ELIGIBILITY TO UNDERGO LYMPHODEPLETION Note: evaluations should be performed no more than 7 days prior to lymphodepletion

    • Research participant with central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation but effectively treated to completion remission (\< 5 white blood cell[WBC]/mm\^3 and no blast in cerebrospinal fluid [CSF]) is eligible to proceed with lymphodepletion
    • Research participants must have a donor or stem cells source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical), unrelated 7/8 or 8/8 allele match) donor, or cord blood stem cell source (at lease 4/6 matched)
    • Research participants with a response less than a CR or complete response with incomplete hematopoietic recovery (CRi) or detectable minimal residual disease (MRD) positive disease
    • Research participant has a released cryopreserved T cell product for CAR T cell infusion on approximately day 0
    • Research participant must be at least 2 weeks out from having received the last dose of agent
    • Karnofsky performance status (KPS) >= 70
    • Documented measurable or evaluable disease
    • Non hematological toxicity related to prior therapy must either have returned to =\< grade 2, baseline, or deemed irreversible
    • Research participants of must agree to use and utilize and adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusion
    • If a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for GVHD for at least 7 days before beginning lymphodepletion
    • Pulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air
    • Cardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension
    • Renal Function: calculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine \< 2.0 mg/dl or \< 2 times upper limit of normal for the research participant's age group
    • Liver Function: adequate liver function defined as total bilirubin =\< 3.0 mg/dl
    • ALT and AST =\< 5 times the institutional upper limits of normal
    • Neurological: research participant without encephalopathy/new focal deficits
    • Infectious diseases: no clinical evidence of uncontrolled active infectious process
  • ELIGIBILITY CRITERIA AT TIME OF INFUSION OF GENETICALLY MODIFIED T CELLS

    • Research participants has undergone lymphodepletion
    • Pulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air
    • Cardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension
    • Renal Function: calculated creatinine clearance (absolute value) of >= 50 mL/minute or creatinine \< 2.0 mg/dl or \< 2 times upper limit of normal for the research participant's age group
    • Liver Function: adequate liver function defined as total bilirubin =\< 3.0 mg/dl
    • ALT and AST =\< 5 times the institutional upper limits of normal
    • Neurological: research participant without clinically significant encephalopathy/new focal deficits
    • Infectious diseases: no clinical evidence of uncontrolled active infectious process
    • Research participant must be off all anti-leukemic drugs, with the exception of the lymphodepleting regimens, at least 7 days prior to CAR T cell infusion
  • ELIGIBILITY CRITERIA TO UNDERGO OPTIONAL T CELL ABLATION

    • Research participant has >= 1% CAR T cells in the peripheral blood
    • Pulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air
    • Cardiovascular: not requiring pressor support, no symptomatic cardiac arrhythmias, no acute coronary syndrome, or uncontrolled hypertension
    • Renal Function: serum creatinine did NOT increase by more than 2.5 fold from baseline (at time of screening)
    • Liver Function: adequate liver function defined as total bilirubin =\< 3.0 mg/dl
    • AST =\< 5 x ULN, ALT =\< 5 x ULN
    • Neurological: research participant without clinically significant encephalopathy/new focal deficits
    • Infectious diseases: no clinical evidence of uncontrolled active infectious process
  • ALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION:

    • Related donor selection will be conducted in accordance with City of Hope's Department of Hematology \& Hematopoietic Cell Transplantation criteria and, in the case of unrelated donor from a transplant center, will comply with the National Marrow Donor Program's (NMDP) donor selection standards; when a potentially eligible recipient of an unrelated donor product from an NMDP Center is identified, the recipient will complete an NMDP search transfer request to allow City of Hope (COH) NMDP staff to contact the NMDP Coordinating Center, who in turn, will contact the donor's prior Donor Center; the search will follow the NMDP Policy for subsequent donation requests; any form deemed appropriate and necessary by the NMDP, including the Subsequent Donation Request Form, Therapeutic T Cell Collection Prescription and Therapeutic Stem Cell Collection Prescription, will be submitted as required
    • In the case of a related donor: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic stem cell transplantation (alloSCT)
    • For both related and unrelated donors: The donor's surface antigen must be negative and the antibody must be nonreactive; in the case of a positive hepatitis C antibody result, the hepatitis C virus (HCV) viral polymerase chain reaction (PCR) will have to be performed and the results should be negative

Exclusion criteria

Exclusion Criteria:

  • Research participants with uncontrolled intercurrent illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements; such social situations include but are not limited to lack of reliable means of transportation for follow up, inability to make time for required clinic visits due to work or family needs, or lack of reliable ways of communication with the study team in the event that the participant is seriously ill
  • Research participants who have tested (HIV) positive, or have active or C infection based on testing performed within 4 weeks of enrollment
  • Research participants with presence of other active . However, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible
  • Pregnant and lactating women are excluded from this study

Study-Specific Exclusion

  • Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab
  • Dependence on :

    • If the participant is undergoing leukapheresis: physiological replacement doses of steroids are allowed - prednisone no more than 7.5 mg, hydrocortisone less than 12 mg/m\^2/day

      • However, all participants must be able to reduce steroid requirement to no more than physiological replacement doses prior to start of lymphodepletion
  • Active disease requiring systemic therapy
  • Research participants will be excluded, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Treatment (lymphodepletion, T-cell immunotherapy)

    Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at \> 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.

    Drug: cyclophosphamide · Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes · Other: laboratory biomarker analysis · Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes · Drug: Fludarabine Phosphate

Interventions

  • Given IV

    Also known as: CPM, CTX, Cytoxan, Endoxan, Endoxana

  • BiologicalAutologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes

    Given IV

    Also known as: CD123R(EQ)28zeta/EGFRt+ T cells, Anti CD123-CAR/CD28-costimulatory Lentiviral Vector-transduced Autologous T Lymphocytes

  • Otherlaboratory biomarker analysis

    Correlative studies

  • BiologicalAllogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes

    Given IV

    Also known as: Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells

  • Given IV

    Also known as: 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Oforta, SH T 586

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) defined as any grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. Tables will summarize all toxicities and side effects by attribution of treatment, dose, time-post treatment, organ and severity. Analysis will be done separately for each disease arm.

    Time frame: 28 days

  2. Incidence of adverse events as assessed by NCI CTCAE version 4.0

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. Tables will summarize all toxicities and side effects by attribution of treatment, dose, time-post treatment, organ and severity. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 years

  3. Disease response (CR or CRi)

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 year post-treatment

Secondary outcomes

  1. Engraftment of transferred CD123+ CAR T cells

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. Analysis will be done separately for each disease arm.

    Time frame: Day 28

  2. CAR123-specific antibody level

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 years

  3. Duration of response

    Will provide descriptive statistics. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 years

  4. Progression Free Survival (PFS)

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated for PFS 6mo. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 years

  5. Survival

    Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated for 1 year OS. Analysis will be done separately for each disease arm.

    Time frame: Up to 15 years

Other outcomes

  1. Number of CD123+ normal cells in peripheral blood and bone marrow

    Percents and counts will be calculated. Analysis will be done separately for each disease arm.

    Time frame: Up to day 14

  2. Number of peripheral blood cell subsets in hematopoietic stem cell compartment

    Percentages and counts will be calculated. Analysis will be done separately for each disease arm.

    Time frame: Up to day 14

  3. Proof of elimination of CD123+ CAR T cells

    Rates and associate 95% Clopper and Pearson binomial confidence limits will be estimated. Descriptive statistics and graphical methods will be used to describe T cell numbers and percentages over time. Analysis will be done separately for each disease arm.

    Time frame: Up to day 14

  4. Number of CD123+ leukemic cells in peripheral blood and bone marrow

    Percents and counts will be calculated. Analysis will be done separately for each disease arm.

    Time frame: Up to day 14

  5. Number of peripheral blood cell subsets in progenitor cell compartment

    Percentages and counts will be calculated. Analysis will be done separately for each disease arm.

    Time frame: Up to day 14

07

Study locations

1 site
08

References and documents

Publications

  • Budde LE, Del Real MM, Song J, Stiller T, Wang Y, Aribi A, Sandhu K, Nakamura R, Marcucci EC, Wu JJ, Ng K, Clark MC, Wood B, Wagner JR, Paul J, Brown CE, Stein A, Marcucci G, Blanchard MS, Palmer J, Forman SJ. A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. J Hematol Oncol. 2026 Aug 7;19(1):68. doi: 10.1186/s13045-026-01833-3. PubMed 42681647 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2015 (actual). Primary completion is estimated for Jul 2027, 138 months after the start.

Of 26 phase 1 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 98. This study's planned 138 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2014
First posted
Jun 10, 2014
StartActual
Dec 15, 2015
Primary completionEst.
Jul 14, 2027
CompletionEst.
Jul 14, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02159495
Collaborators
National Cancer Institute (NCI), Mustang Bio, Inc.
Responsible party
Sponsor
First posted
Jun 10, 2014
Start date
Dec 15, 2015
Primary completion
Jul 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Lihua E. Budde
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion